Technical Analysis for RVPH - Reviva Pharmaceuticals Holdings, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 3.08 | -2.22% | -0.07 |
RVPH closed down 2.22 percent on Monday, March 18, 2024, on 72 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | -2.22% | |
Lower Bollinger Band Walk | Weakness | -2.22% | |
New 52 Week Low | Weakness | -2.22% |
Alert | Time |
---|---|
Down 3% | about 21 hours ago |
Gap Up Closed | about 21 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Down 2 % | about 21 hours ago |
Down 1% | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/28/2024
Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Inflammatory Diseases Schizophrenia Major Depressive Disorder Psychiatric Diagnosis Psychiatry Stage Pharmaceutical Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Chloroarenes Bipolar Disorder Pulmonary Hypertension Treatment Of Schizophrenia Piperazines
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Inflammatory Diseases Schizophrenia Major Depressive Disorder Psychiatric Diagnosis Psychiatry Stage Pharmaceutical Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Chloroarenes Bipolar Disorder Pulmonary Hypertension Treatment Of Schizophrenia Piperazines
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.2499 |
52 Week Low | 2.8 |
Average Volume | 308,691 |
200-Day Moving Average | 4.62 |
50-Day Moving Average | 3.99 |
20-Day Moving Average | 3.73 |
10-Day Moving Average | 3.36 |
Average True Range | 0.26 |
RSI (14) | 31.51 |
ADX | 25.12 |
+DI | 15.39 |
-DI | 29.53 |
Chandelier Exit (Long, 3 ATRs) | 3.81 |
Chandelier Exit (Short, 3 ATRs) | 3.58 |
Upper Bollinger Bands | 4.67 |
Lower Bollinger Band | 2.79 |
Percent B (%b) | 0.16 |
BandWidth | 50.37 |
MACD Line | -0.30 |
MACD Signal Line | -0.22 |
MACD Histogram | -0.079 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.58 | ||||
Resistance 3 (R3) | 3.61 | 3.48 | 3.49 | ||
Resistance 2 (R2) | 3.48 | 3.35 | 3.46 | 3.46 | |
Resistance 1 (R1) | 3.28 | 3.28 | 3.22 | 3.25 | 3.44 |
Pivot Point | 3.15 | 3.15 | 3.12 | 3.13 | 3.15 |
Support 1 (S1) | 2.95 | 3.02 | 2.89 | 2.92 | 2.72 |
Support 2 (S2) | 2.82 | 2.95 | 2.80 | 2.70 | |
Support 3 (S3) | 2.62 | 2.82 | 2.67 | ||
Support 4 (S4) | 2.59 |